Litigation Details for TEVA PHARMACEUTICALS USA, INC. v. SYNTHON PHARMACEUTICALS, INC. (M.D.N.C. 2014)

TEVA PHARMACEUTICALS USA, INC. v. SYNTHON PHARMACEUTICALS, INC. (M.D.N.C. 2014)

Docket		Date Filed	2014-11-19
Court	District Court, M.D. North Carolina	Date Terminated	2015-02-12
Cause	35:271 Patent Infringement	Assigned To	Loretta Copeland Biggs
Jury Demand	None	Referred To	Joe L. Webster
Patents	8,232,250; 8,399,413
Link to Docket	External link to docket

Details for TEVA PHARMACEUTICALS USA, INC. v. SYNTHON PHARMACEUTICALS, INC. (M.D.N.C. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-11-19				External link to document

Teva Pharmaceuticals USA v. Synthon Pharmaceuticals, 1:14-cv-00975: Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Teva Pharmaceuticals USA sued Synthon Pharmaceuticals in the U.S. District Court for the District of Delaware after Synthon filed an abbreviated new drug application for a generic version of Copaxone, Teva’s glatiramer acetate injection. The case concerned Teva’s later-expiring Copaxone formulation patents, including U.S. Patent Nos. 8,232,250 and 8,399,413. The action ended through a stipulated dismissal rather than a reported trial judgment or appellate decision. Public docket materials do not disclose the commercial terms of the parties’ resolution. [1]

What drug and ANDA were at issue in Teva v. Synthon?

The litigation involved glatiramer acetate injection, marketed by Teva as Copaxone.

Item	Details
Brand drug	Copaxone
Active ingredient	Glatiramer acetate
Sponsor	Teva Pharmaceuticals USA, Inc.
Original FDA application	NDA 020622
Dosage forms	Injectable solution, including 20 mg/mL and 40 mg/mL presentations
Generic applicant	Synthon Pharmaceuticals, Inc.
Regulatory pathway	ANDA
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:14-cv-00975
Filing year	2014
Case outcome	Stipulated dismissal without a reported merits judgment

Glatiramer acetate is a synthetic polypeptide mixture used to reduce relapse frequency in patients with relapsing forms of multiple sclerosis. Copaxone was one of Teva’s largest specialty pharmaceutical products and generated substantial revenue before generic competition developed.

What patents did Teva assert against Synthon?

The case is associated with Teva’s later-generation Copaxone patents, principally U.S. Patent Nos. 8,232,250 and 8,399,413. These patents addressed pharmaceutical compositions and injectable glatiramer acetate formulations rather than only the original active-ingredient concept. [1]

Patent	General subject matter	Relevance to Copaxone	Approximate listed expiration
U.S. 8,232,250	Glatiramer acetate pharmaceutical composition and injection	Formulation and dosage-related protection	2025, subject to applicable patent-term adjustments
U.S. 8,399,413	Glatiramer acetate composition and injectable product	Later formulation protection	2030, subject to applicable patent-term adjustments

The precise claim scope depended on the asserted claims and Synthon’s ANDA product. In an ANDA case, Teva’s infringement theory generally would have focused on whether the proposed generic product, its labeling, or its manufacturing specifications fell within the patent claims under 35 U.S.C. § 271(e)(2).

The initial case should be distinguished from later Copaxone litigation involving continuation patents, including U.S. Patent No. 8,969,302. The existence of later Orange Book-listed patents did not automatically make each later patent part of the Synthon case.

What was the legal basis for the Teva v. Synthon lawsuit?

Teva filed the action under the Hatch-Waxman patent litigation framework. Synthon’s ANDA filing and Paragraph IV certification created a statutory act of infringement, allowing Teva to sue before commercial marketing of the generic product. [2]

The principal legal issues in this type of case were:

1. Whether Synthon’s proposed glatiramer acetate product would infringe the asserted formulation claims.
2. Whether the asserted claims were valid under the Patent Act.
3. Whether Synthon could establish noninfringement, invalidity, or both.
4. Whether Teva was entitled to an injunction blocking FDA approval or commercial launch.
5. Whether a settlement would permit a future generic entry date before patent expiration.

The public disposition does not show a substantive court ruling on claim construction, infringement, validity, inequitable conduct, or patent eligibility. The case therefore provides limited precedent on the merits.

Was Synthon’s ANDA a Paragraph IV challenge?

The suit indicates that Synthon’s ANDA included a certification that triggered Teva’s patent infringement claims. In Hatch-Waxman practice, a Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

A Paragraph IV notice can create a 45-day period for the NDA holder to file suit. A timely suit generally imposes an automatic FDA approval stay of up to 30 months, subject to statutory exceptions and court orders. [2]

The public case record does not establish that the court reached a final determination that Synthon’s product infringed the asserted patents. The dismissal ended the dispute without a reported opinion establishing the commercial launch date or the parties’ allocation of patent risk.

What was the litigation timeline?

Date or period	Event
Before August 2014	Synthon filed an ANDA for a generic glatiramer acetate injection and provided notice implicating Teva’s listed patents.
August 2014	Teva filed Civil Action No. 1:14-cv-00975 in the District of Delaware.
2014-2015	The parties litigated the ANDA patent dispute under the Hatch-Waxman framework.
Subsequent docket period	The action was resolved through a stipulated dismissal.
Final disposition	No reported trial verdict, claim-construction ruling, Federal Circuit decision, or merits judgment appears in the case record.

The case number identifies a Delaware federal action filed in 2014. The docket’s dismissal mechanism is material: a stipulated dismissal typically indicates that the parties resolved the dispute privately or that the ANDA-related controversy no longer required adjudication. It does not establish that Synthon conceded validity or infringement.

Did Teva and Synthon enter a settlement agreement?

The case ended by stipulated dismissal, but publicly available docket materials do not disclose the settlement’s business terms. The record does not establish:

• Synthon’s agreed launch date;
• Whether Synthon received a license;
• Whether Teva provided a royalty-bearing license;
• Whether Synthon agreed not to launch until a specified patent date;
• Whether the agreement included supply, development, or co-marketing provisions;
• Whether the Federal Trade Commission reviewed or challenged the agreement.

A dismissal alone cannot be treated as a finding that Teva’s patents were strong or that Synthon’s ANDA was weak. It also cannot be used to infer a launch date without the underlying settlement or a later commercial announcement.

What was the Orange Book status of Copaxone?

Copaxone was approved under NDA 020622 and listed in the FDA Orange Book with patent information covering the reference product. The relevant patent estate included formulation and injection patents that extended protection beyond the earlier basic Copaxone patents. [3]

The Orange Book distinguishes between:

• patents claiming the drug substance;
• patents claiming a drug product or formulation;
• method-of-use patents;
• patents that may be subject to different certification and labeling strategies.

For glatiramer acetate, the commercial importance of the formulation patents was high because the active ingredient had been marketed for years before the asserted later patents expired. Product and formulation claims could therefore delay generic entry even after earlier composition patents ceased to block approval.

The Orange Book does not disclose private settlement terms. It also does not indicate whether a particular ANDA applicant ultimately launched, withdrew its application, or transferred development rights.

When did Copaxone lose exclusivity?

Copaxone lost practical exclusivity in stages rather than on a single date.

Regulatory exclusivity

FDA marketing exclusivity for the original NDA was separate from patent protection. Copaxone’s principal commercial barriers were patent rights and the technical complexity of demonstrating pharmaceutical equivalence for a synthetic polypeptide mixture.

Patent exclusivity

The earlier Copaxone patents expired before the later formulation patents. The later patents listed in connection with Copaxone extended potential market protection into the mid-2020s and, for certain patents, toward 2030. The actual generic entry date depended on patent litigation, Paragraph IV settlements, pediatric exclusivity, patent-term adjustments, and FDA approval timing.

Generic competition

FDA approved generic glatiramer acetate products from companies including Sandoz and Mylan. FDA approval of a competitor did not automatically establish that Synthon had obtained approval or commercialized its own product. [4]

What generic entry risks did Synthon create for Teva?

Synthon posed four principal risks to Teva’s Copaxone franchise.

Early entry risk

A successful Paragraph IV challenge could have resulted in FDA approval and commercial launch before the asserted patents expired. Generic entry would have reduced Copaxone pricing and shifted prescriptions to lower-cost alternatives.

Formulation substitution risk

Glatiramer acetate products compete on more than active ingredient identity. Injection frequency, concentration, device compatibility, labeling, and patient familiarity affect substitution and market share. A generic product directed to the 40 mg/mL three-times-weekly regimen could have targeted an important segment of Teva’s franchise.

Price erosion

Multiple generic approvals would likely have accelerated price reductions. The effect would depend on the number of approved applicants, state substitution rules, payer contracting, and the degree of physician and patient switching.

Product-line erosion

Copaxone revenue was exposed to both direct generic substitution and migration to other multiple sclerosis treatments. The risk was greater for an established product with no meaningful patent barrier covering every commercial presentation indefinitely.

How strong was Teva’s patent estate in this case?

Teva’s estate had meaningful commercial strength because it included later formulation patents, but the litigation record does not support a definitive merits assessment.

Strength factor	Assessment
Regulatory listing	Orange Book-listed Copaxone patents created a recognized Hatch-Waxman litigation pathway.
Patent duration	Later patents potentially extended protection materially beyond the earliest Copaxone patents.
Claim type	Formulation and injectable-product claims could be difficult to design around if they covered clinically relevant product attributes.
Validity exposure	The patents were vulnerable to ordinary Paragraph IV attacks, including written description, enablement, obviousness, and claim-construction challenges.
Litigation result	No public merits decision established enforceability or validity in the Synthon action.
Commercial leverage	The prospect of delayed approval gave Teva settlement leverage, but the private resolution prevents quantification.

The strongest feature was the presence of product-specific formulation protection. The principal weakness was that formulation patents are often subject to detailed obviousness and claim-scope disputes, especially where the active ingredient and broad therapeutic use are already known.

Did the case affect biosimilar risk?

No. Biosimilar law did not govern this case.

Glatiramer acetate is regulated through the ANDA pathway rather than the biologics license application and biosimilar pathway. The product is a synthetic polypeptide mixture, and the relevant generic approval framework was Hatch-Waxman. Accordingly, the commercial risk was generic competition, not biosimilar substitution under the Public Health Service Act.

The regulatory complexity of glatiramer acetate could still raise technical development barriers. FDA has treated the product as suitable for an abbreviated approval pathway, but an applicant must address pharmaceutical equivalence, active-ingredient characterization, manufacturing controls, and product quality. [4]

Which companies challenged or competed with Copaxone?

The principal competitive set included generic developers and disease-modifying therapy manufacturers.

Company	Product or role	Competitive significance
Synthon	ANDA applicant in the 2014 Teva case	Created a patent and future-entry threat
Sandoz	Generic glatiramer acetate	Early generic competition
Mylan	Generic glatiramer acetate	Increased generic supply and pricing pressure
Teva	Copaxone reference-product sponsor	Patent holder and incumbent manufacturer
Biogen, Merck, Roche and other MS manufacturers	Alternative disease-modifying therapies	Reduced dependence on glatiramer acetate over time

The Copaxone market was affected by both generic substitution and therapeutic substitution. Oral and infused multiple sclerosis treatments expanded the competitive field beyond injectable glatiramer acetate.

What was the revenue exposure for Teva?

Copaxone historically represented a major portion of Teva’s revenue and profitability. Its financial exposure arose from:

• loss of branded volume after generic approval;
• net-price erosion from payer and pharmacy substitution;
• reduced persistence of the branded product;
• higher rebates to defend formulary position;
• migration to competing multiple sclerosis therapies.

The 2014 Synthon action was commercially significant because the asserted patents represented part of Teva’s strategy to protect Copaxone after the expiration of older patent rights. The private resolution prevented a public determination of whether Synthon could have entered before those later patents expired.

What manufacturing and intellectual-property barriers applied?

Glatiramer acetate is not a simple small-molecule product. Manufacturing consistency is important because the active ingredient is a heterogeneous mixture of polypeptides rather than a single precisely defined molecule.

Relevant barriers included:

• control of molecular-weight distribution;
• reproducibility of amino-acid composition;
• purification and impurity controls;
• batch-to-batch consistency;
• injectable formulation stability;
• device and container compatibility;
• analytical characterization;
• regulatory comparability.

These factors can increase development cost and reduce the number of credible generic entrants. They do not, however, eliminate patent invalidity or noninfringement defenses.

What is the current litigation significance of Teva v. Synthon?

The case is significant as a Copaxone ANDA dispute involving later formulation patents, but it is not a precedent-setting decision. Its principal business implications are:

1. Teva used Orange Book-listed formulation patents to challenge a potential generic entrant.
2. Synthon’s challenge was resolved without a public merits ruling.
3. The dismissal leaves the settlement terms and any agreed entry date confidential.
4. The case demonstrates the commercial value of later product patents after earlier active-ingredient protection has expired.
5. The dispute should be analyzed with later Copaxone cases rather than in isolation.

Key Takeaways

• Teva sued Synthon in Delaware in 2014 over an ANDA for generic glatiramer acetate injection.
• The dispute involved Teva’s Copaxone formulation patents, including U.S. Patent Nos. 8,232,250 and 8,399,413.
• The case ended through stipulated dismissal and produced no reported merits ruling.
• Public docket materials do not disclose the settlement terms or Synthon’s authorized launch date.
• The case involved generic, not biosimilar, competition.
• Copaxone’s commercial protection depended heavily on later formulation patents after earlier patent rights expired.
• FDA-approved generic competition from other companies later created substantial price and volume pressure on Teva.

FAQs About Teva Pharmaceuticals USA v. Synthon

Did Synthon win the Teva Copaxone patent case?

No public merits judgment shows that Synthon won. The action ended through stipulated dismissal, which does not establish a ruling on infringement, validity, or enforceability.

Was Synthon allowed to launch generic Copaxone?

The public case disposition does not establish Synthon’s authorized launch date. A stipulated dismissal alone does not identify whether the parties agreed to a license or delayed entry.

Which Copaxone patent was most important in the Synthon litigation?

The case is associated with U.S. Patent Nos. 8,232,250 and 8,399,413, which covered later-generation glatiramer acetate formulation and injection technology.

Did Teva’s Copaxone patents cover the active ingredient itself?

The asserted patents were primarily associated with pharmaceutical composition and injectable formulation protection. They should be distinguished from earlier patents directed more broadly to glatiramer acetate or related copolymer technology.

Was the Synthon case consolidated with Teva’s litigation against Sandoz or Mylan?

The Synthon action was a separate Delaware civil action. Its stipulated dismissal did not itself create a merits ruling applicable to other Copaxone defendants.

References

1. U.S. District Court for the District of Delaware. (2014). Teva Pharmaceuticals USA, Inc. v. Synthon Pharmaceuticals, Inc., No. 1:14-cv-00975. PACER case docket and filings.

2. U.S. Code. (2024). 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2). Hatch-Waxman abbreviated new drug application provisions.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Glatiramer acetate injection products and abbreviated new drug applications. FDA drug approval records.